LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.9838 USD -9.74% Market Closed
Market Cap: 25.9m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

LAVA Therapeutics NV
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Total Liabilities & Equity
$101.7m
CAGR 3-Years
71%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Total Liabilities & Equity
$425.5m
CAGR 3-Years
7%
CAGR 5-Years
14%
CAGR 10-Years
26%
ProQR Therapeutics NV
NASDAQ:PRQR
Total Liabilities & Equity
€106.9m
CAGR 3-Years
-18%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Total Liabilities & Equity
$645.8m
CAGR 3-Years
-6%
CAGR 5-Years
6%
CAGR 10-Years
18%
argenx SE
XBRU:ARGX
Total Liabilities & Equity
$4.8B
CAGR 3-Years
14%
CAGR 5-Years
37%
CAGR 10-Years
71%
Merus NV
NASDAQ:MRUS
Total Liabilities & Equity
$844.7m
CAGR 3-Years
33%
CAGR 5-Years
32%
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
25.9m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.1828 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Total Liabilities & Equity?
Total Liabilities & Equity
101.7m USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Total Liabilities & Equity amounts to 101.7m USD.

What is LAVA Therapeutics NV's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 3Y
71%

Over the last year, the Total Liabilities & Equity growth was -29%. The average annual Total Liabilities & Equity growth rates for LAVA Therapeutics NV have been 71% over the past three years .

Back to Top